Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8751046,relative bioavailability (f'P-GS),(iii) An approximated relative bioavailability (f'P-GS) of 36.5% was calculated.,Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751046/),%,36.5,716,DB00457,Prazosin
,2951051,half-life (t1/2),"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),h,19.4,3877,DB00457,Prazosin
,2951051,half-life (t1/2),"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),h,18.7,3878,DB00457,Prazosin
,2951051,half-life (t1/2),"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),h,19.7,3879,DB00457,Prazosin
,2951051,volume of distribution,"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),[l] / [kg],3.4,3880,DB00457,Prazosin
,2951051,volume of distribution,"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),[l] / [kg],3.6,3881,DB00457,Prazosin
,2951051,clearance from serum,"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),[ml] / [kg·min],2.2,3882,DB00457,Prazosin
,2951051,clearance from serum,"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),[ml] / [kg·min],2.1,3883,DB00457,Prazosin
,2951051,clearance from serum,"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),%,1,3884,DB00457,Prazosin
,2951051,clearance from serum,"Increases in doses from 2 to 8 mg (steady state) produced proportional increases in doxazosin serum levels (maximum plasma drug concentration [Cmax] minimum plasma drug concentration [C min], and O-24-hour area under the curve [AUC(p-24)], whereas half-life (t1/2) (19.4, 18.7, and 19.7 hours, respectively), volume of distribution (3.4, 3.4, and 3.6 L/kg, respectively), clearance from serum (2.2, 2.2, and 2.1 ml/min/kg, respectively), and degree of protein binding (1.2%, 1.0%, and 1.0% unbound, respectively) were dose independent.",Clinical pharmacology of doxazosin in patients with essential hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),%,1.0,3885,DB00457,Prazosin
,2951051,tmax,"Peak hypotensive and tachycardic effects occurred 5.7 +/- 0.1 hours after administration, whereas Cmax was achieved at 2.4 +/- 0.7 hours (tmax).",Clinical pharmacology of doxazosin in patients with essential hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951051/),h,2.4,3886,DB00457,Prazosin
,2441167,detection limit,Concentrations of prazosin and terazosin were measured using a high-performance liquid chromatographic procedure with a detection limit of approximately 0.25 ng/ml.,Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441167/),[ng] / [ml],0.25,7224,DB00457,Prazosin
,3598910,unbound fraction,"Administration of 40 and 100 mg/kg of AAG decreased the unbound fraction in plasma of prazosin from 0.238 to 0.175 and 0.090, respectively.",Decreased elimination of unbound prazosin in the presence of alpha 1-acid glycoprotein in the rat in vivo. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598910/),,0.238,18553,DB00457,Prazosin
,3598910,unbound fraction,"Administration of 40 and 100 mg/kg of AAG decreased the unbound fraction in plasma of prazosin from 0.238 to 0.175 and 0.090, respectively.",Decreased elimination of unbound prazosin in the presence of alpha 1-acid glycoprotein in the rat in vivo. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598910/),,0.175,18554,DB00457,Prazosin
,3598910,unbound fraction,"Administration of 40 and 100 mg/kg of AAG decreased the unbound fraction in plasma of prazosin from 0.238 to 0.175 and 0.090, respectively.",Decreased elimination of unbound prazosin in the presence of alpha 1-acid glycoprotein in the rat in vivo. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598910/),,0.090,18555,DB00457,Prazosin
,3598910,"apparent volume of distribution of unbound drug, steady state, VUss","The apparent volume of distribution of unbound drug, steady state, VUss, decreased from 12.4 to 7.7 liters/kg, and the red blood cell/plasma water concentration ratio decreased from 9.2 to 4.0 after administration of AAG.",Decreased elimination of unbound prazosin in the presence of alpha 1-acid glycoprotein in the rat in vivo. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598910/),[l] / [kg],12.4 to 7.7,18556,DB00457,Prazosin
,3598910,red blood cell/plasma water concentration ratio,"The apparent volume of distribution of unbound drug, steady state, VUss, decreased from 12.4 to 7.7 liters/kg, and the red blood cell/plasma water concentration ratio decreased from 9.2 to 4.0 after administration of AAG.",Decreased elimination of unbound prazosin in the presence of alpha 1-acid glycoprotein in the rat in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598910/),,9.2,18557,DB00457,Prazosin
,3598910,red blood cell/plasma water concentration ratio,"The apparent volume of distribution of unbound drug, steady state, VUss, decreased from 12.4 to 7.7 liters/kg, and the red blood cell/plasma water concentration ratio decreased from 9.2 to 4.0 after administration of AAG.",Decreased elimination of unbound prazosin in the presence of alpha 1-acid glycoprotein in the rat in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598910/),,4.0,18558,DB00457,Prazosin
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,4.5,21462,DB00457,Prazosin
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,8.5,21463,DB00457,Prazosin
,27795624,time to first increase in dose,Mean time to first increase in dose was 6.5 ± 3.6 days.,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),d,6.5,21464,DB00457,Prazosin
,3325090,QT interval (QTc),4. The QT interval (QTc) was significantly increased after 1 month's treatment: at 1 h after dosing 334 +/- 32 ms after 1 month of ketanserin compared with 302 +/- 31 ms after placebo.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),ms,334,28215,DB00457,Prazosin
,3325090,QT interval (QTc),4. The QT interval (QTc) was significantly increased after 1 month's treatment: at 1 h after dosing 334 +/- 32 ms after 1 month of ketanserin compared with 302 +/- 31 ms after placebo.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),ms,302,28216,DB00457,Prazosin
,3325090,elimination half-life,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),h,13.4,28217,DB00457,Prazosin
,3325090,half-life,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),h,4.3,28218,DB00457,Prazosin
,3325090,AUC,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),[h·ng] / [ml],830,28219,DB00457,Prazosin
,3325090,AUC,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),[h·ng] / [ml],437,28220,DB00457,Prazosin
,6794530,t max,"The rate of absorption of prazosin was identical in the two groups (t max: I,3 +/- 0,2 h and I,6 +/- 0,4 h).",[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794530/),h,3,30402,DB00457,Prazosin
,6794530,t max,"The rate of absorption of prazosin was identical in the two groups (t max: I,3 +/- 0,2 h and I,6 +/- 0,4 h).",[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794530/),h,6,30403,DB00457,Prazosin
,6794530,Maximal serum concentrations,"Maximal serum concentrations were significantly higher in Group I (33,5 +/- 3,7 microgram/1 compared to 22,0 +/- 2.5 microgram/l, p less than 0,02) as was the surface under the serum concentration curve plotted against time (206,I +/- 31.I microgram.h.l-1 compared to 99,9 +/- 12,3 microgram.h.l-1, p less than 0,01).",[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794530/),μg,"33,5",30404,DB00457,Prazosin
,6794530,Maximal serum concentrations,"Maximal serum concentrations were significantly higher in Group I (33,5 +/- 3,7 microgram/1 compared to 22,0 +/- 2.5 microgram/l, p less than 0,02) as was the surface under the serum concentration curve plotted against time (206,I +/- 31.I microgram.h.l-1 compared to 99,9 +/- 12,3 microgram.h.l-1, p less than 0,01).",[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794530/),[μg] / [l],"22,0",30405,DB00457,Prazosin
,6794530,surface under the serum concentration curve,"Maximal serum concentrations were significantly higher in Group I (33,5 +/- 3,7 microgram/1 compared to 22,0 +/- 2.5 microgram/l, p less than 0,02) as was the surface under the serum concentration curve plotted against time (206,I +/- 31.I microgram.h.l-1 compared to 99,9 +/- 12,3 microgram.h.l-1, p less than 0,01).",[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794530/),[h·μg] / [l],"206,I",30406,DB00457,Prazosin
,6794530,surface under the serum concentration curve,"Maximal serum concentrations were significantly higher in Group I (33,5 +/- 3,7 microgram/1 compared to 22,0 +/- 2.5 microgram/l, p less than 0,02) as was the surface under the serum concentration curve plotted against time (206,I +/- 31.I microgram.h.l-1 compared to 99,9 +/- 12,3 microgram.h.l-1, p less than 0,01).",[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794530/),[h·μg] / [l],"99,9",30407,DB00457,Prazosin
,2441160,Cmax,"The pharmacokinetic parameters of doxazosin in both single- and consecutive-dose study were 18.9 and 25.8 ng/ml in Cmax, 11.1 and 12.9 h in half life (t1/2), and 182.0 and 273.0 ng h/ml in area under the curve (AUC)24(0), respectively.",Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441160/),[ng] / [ml],18.9,36393,DB00457,Prazosin
,2441160,Cmax,"The pharmacokinetic parameters of doxazosin in both single- and consecutive-dose study were 18.9 and 25.8 ng/ml in Cmax, 11.1 and 12.9 h in half life (t1/2), and 182.0 and 273.0 ng h/ml in area under the curve (AUC)24(0), respectively.",Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441160/),[ng] / [ml],25.8,36394,DB00457,Prazosin
,2441160,half life (t1/2),"The pharmacokinetic parameters of doxazosin in both single- and consecutive-dose study were 18.9 and 25.8 ng/ml in Cmax, 11.1 and 12.9 h in half life (t1/2), and 182.0 and 273.0 ng h/ml in area under the curve (AUC)24(0), respectively.",Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441160/),h,11.1,36395,DB00457,Prazosin
,2441160,half life (t1/2),"The pharmacokinetic parameters of doxazosin in both single- and consecutive-dose study were 18.9 and 25.8 ng/ml in Cmax, 11.1 and 12.9 h in half life (t1/2), and 182.0 and 273.0 ng h/ml in area under the curve (AUC)24(0), respectively.",Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441160/),h,12.9,36396,DB00457,Prazosin
,2441160,area under the curve (AUC)24(0),"The pharmacokinetic parameters of doxazosin in both single- and consecutive-dose study were 18.9 and 25.8 ng/ml in Cmax, 11.1 and 12.9 h in half life (t1/2), and 182.0 and 273.0 ng h/ml in area under the curve (AUC)24(0), respectively.",Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441160/),[h·ng] / [ml],182.0,36397,DB00457,Prazosin
,2441160,area under the curve (AUC)24(0),"The pharmacokinetic parameters of doxazosin in both single- and consecutive-dose study were 18.9 and 25.8 ng/ml in Cmax, 11.1 and 12.9 h in half life (t1/2), and 182.0 and 273.0 ng h/ml in area under the curve (AUC)24(0), respectively.",Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441160/),[h·ng] / [ml],273.0,36398,DB00457,Prazosin
,7285477,Terminal half-life (t1/2 beta),Terminal half-life (t1/2 beta) was about 3 hr and apparent volume of distribution (Vd beta) about 0.6 l/kg.,Prazosin kinetics in hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285477/),h,3,36959,DB00457,Prazosin
,7285477,apparent volume of distribution (Vd beta),Terminal half-life (t1/2 beta) was about 3 hr and apparent volume of distribution (Vd beta) about 0.6 l/kg.,Prazosin kinetics in hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285477/),[l] / [kg],0.6,36960,DB00457,Prazosin
,7285477,bioavailability,After oral doses bioavailability ranged between 55% and 82%.,Prazosin kinetics in hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285477/),%,55,36961,DB00457,Prazosin
,7285477,bioavailability,After oral doses bioavailability ranged between 55% and 82%.,Prazosin kinetics in hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285477/),%,82,36962,DB00457,Prazosin
,7285477,total plasma clearance,Since total plasma clearance was low (0.14 l/kg x hr) incomplete bioavailability was the result of incomplete absorption rather than of first-pass liver metabolism.,Prazosin kinetics in hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285477/),[l] / [h·kg],0.14,36963,DB00457,Prazosin
,7285477,extraction ratio,The estimated extraction ratio was about 14%.,Prazosin kinetics in hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285477/),%,14,36964,DB00457,Prazosin
,10631624,peak plasma concentrations,"The mean peak plasma concentrations were 10.8 ng/mL and 12.3 ng/mL for the subjects with hepatic impairment and healthy subjects, respectively.",The effects of hepatic impairment on the pharmacokinetics of doxazosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631624/),[ng] / [ml],10.8,38244,DB00457,Prazosin
,10631624,peak plasma concentrations,"The mean peak plasma concentrations were 10.8 ng/mL and 12.3 ng/mL for the subjects with hepatic impairment and healthy subjects, respectively.",The effects of hepatic impairment on the pharmacokinetics of doxazosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631624/),[ng] / [ml],12.3,38245,DB00457,Prazosin
,10631624,area under the plasma concentration-time curve,"The corresponding mean area under the plasma concentration-time curve values were 246 and 172 ng.h/mL, a 43% increase in exposure in the subjects with hepatic impairment (p = 0.02).",The effects of hepatic impairment on the pharmacokinetics of doxazosin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631624/),[h·ng] / [ml],246,38246,DB00457,Prazosin
,10631624,area under the plasma concentration-time curve,"The corresponding mean area under the plasma concentration-time curve values were 246 and 172 ng.h/mL, a 43% increase in exposure in the subjects with hepatic impairment (p = 0.02).",The effects of hepatic impairment on the pharmacokinetics of doxazosin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631624/),[h·ng] / [ml],172,38247,DB00457,Prazosin
,10631624,elimination halflife,"Although the apparent oral clearance was reduced by 30% in men with hepatic impairment compared with healthy subjects (p = 0.02), the elimination halflife was not significantly changed (24 vs. 22 hours, respectively).",The effects of hepatic impairment on the pharmacokinetics of doxazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631624/),h,24,38248,DB00457,Prazosin
,10631624,elimination halflife,"Although the apparent oral clearance was reduced by 30% in men with hepatic impairment compared with healthy subjects (p = 0.02), the elimination halflife was not significantly changed (24 vs. 22 hours, respectively).",The effects of hepatic impairment on the pharmacokinetics of doxazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631624/),h,22,38249,DB00457,Prazosin
,20732837,flow rate,"Baseline chiral separation was obtained within 9 min on an ovomucoid column using an isocratic mobile phase of methanol/5mM ammonium acetate/formic acid (20/80/0.016, v/v/v) at a flow rate of 0.60 mL/min.",Enantioselective determination of doxazosin in human plasma by liquid chromatography-tandem mass spectrometry using ovomucoid chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20732837/),[ml] / [min],0.60,51434,DB00457,Prazosin
,2884857,oral bioavailability,"For single doses, oral bioavailability has been calculated to be about 65%; terminal elimination half-life is approximately 10 to 12 hours.",Pharmacokinetic overview of doxazosin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884857/),%,65,57403,DB00457,Prazosin
,2884857,terminal elimination half-life,"For single doses, oral bioavailability has been calculated to be about 65%; terminal elimination half-life is approximately 10 to 12 hours.",Pharmacokinetic overview of doxazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884857/),h,10 to 12,57404,DB00457,Prazosin
,2884857,terminal elimination half-life,"In later multiple-dose studies in which doxazosin concentrations were measured beyond 24 hours after administration, the terminal elimination half-life was 22 hours.",Pharmacokinetic overview of doxazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884857/),h,22,57405,DB00457,Prazosin
,2884857,Protein binding,Protein binding is reported to be 98.3% in humans.,Pharmacokinetic overview of doxazosin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884857/),%,98.3,57406,DB00457,Prazosin
,2884857,clearance,Relatively low clearance (1.0 to 2.0 ml/min/kg) in association with a moderate volume of distribution (1.0 to 1.9 liters/kg) is responsible for doxazosin's relatively long plasma half-life.,Pharmacokinetic overview of doxazosin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884857/),[ml] / [kg·min],1.0 to 2.0,57407,DB00457,Prazosin
,2884857,volume of distribution,Relatively low clearance (1.0 to 2.0 ml/min/kg) in association with a moderate volume of distribution (1.0 to 1.9 liters/kg) is responsible for doxazosin's relatively long plasma half-life.,Pharmacokinetic overview of doxazosin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884857/),[l] / [kg],1.0 to 1.9,57408,DB00457,Prazosin
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),mmhg,108,57623,DB00457,Prazosin
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),mmhg,61,57624,DB00457,Prazosin
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),mmhg,112,57625,DB00457,Prazosin
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),,122,57626,DB00457,Prazosin
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),,116,57627,DB00457,Prazosin
,8491245,liver blood flow,The introduction of nifedipine in Group 2 was associated with a significant increase in liver blood flow at 1.5 h: 1560 vs 1050 ml.min-1 during monotherapy with doxazosin.,The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),[ml] / [min],1560,57628,DB00457,Prazosin
,8491245,liver blood flow,The introduction of nifedipine in Group 2 was associated with a significant increase in liver blood flow at 1.5 h: 1560 vs 1050 ml.min-1 during monotherapy with doxazosin.,The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),[ml] / [min],1050,57629,DB00457,Prazosin
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,257,57630,DB00457,Prazosin
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,307,57631,DB00457,Prazosin
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,301,57632,DB00457,Prazosin
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,256,57633,DB00457,Prazosin
,8929232,plasma peak concentration (Cmax),"Pharmacokinetic studies in normotensive volunteers showed that plasma peak concentration (Cmax) of bunazosin retard and bioavailability were approximately 50% and 81%, respectively, of the values of the standard non-retarded formulation.",Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929232/),%,50,62568,DB00457,Prazosin
,8929232,plasma peak concentration (Cmax),"Pharmacokinetic studies in normotensive volunteers showed that plasma peak concentration (Cmax) of bunazosin retard and bioavailability were approximately 50% and 81%, respectively, of the values of the standard non-retarded formulation.",Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929232/),%,81,62569,DB00457,Prazosin
,8929232,bioavailability,"Pharmacokinetic studies in normotensive volunteers showed that plasma peak concentration (Cmax) of bunazosin retard and bioavailability were approximately 50% and 81%, respectively, of the values of the standard non-retarded formulation.",Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929232/),%,50,62570,DB00457,Prazosin
,8929232,bioavailability,"Pharmacokinetic studies in normotensive volunteers showed that plasma peak concentration (Cmax) of bunazosin retard and bioavailability were approximately 50% and 81%, respectively, of the values of the standard non-retarded formulation.",Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929232/),%,81,62571,DB00457,Prazosin
,8929232,Cmax,"Following oral administration of 6 mg bunazosin retard to healthy volunteers, Cmax was 15 ng/ml, time to reach peak level (tmax) was 4 h and elimination half life was about 12 h.",Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929232/),[ng] / [ml],15,62572,DB00457,Prazosin
,8929232,time to reach peak level (tmax),"Following oral administration of 6 mg bunazosin retard to healthy volunteers, Cmax was 15 ng/ml, time to reach peak level (tmax) was 4 h and elimination half life was about 12 h.",Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929232/),h,4,62573,DB00457,Prazosin
,8929232,elimination half life,"Following oral administration of 6 mg bunazosin retard to healthy volunteers, Cmax was 15 ng/ml, time to reach peak level (tmax) was 4 h and elimination half life was about 12 h.",Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929232/),h,12,62574,DB00457,Prazosin
,33620010,steady-state penetration rate,"The results showed that the steady-state penetration rate of TEH increased (from 80.36 µg·cm-2·h-1 to 304.93 µg·cm-2·h-1), followed by an increase in the current intensity (from 0.10 mA·cm-2 to 0.49 mA·cm-2).",Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33620010/),[μg] / [(cm)^2·h],80.36,75020,DB00457,Prazosin
,33620010,steady-state penetration rate,"The results showed that the steady-state penetration rate of TEH increased (from 80.36 µg·cm-2·h-1 to 304.93 µg·cm-2·h-1), followed by an increase in the current intensity (from 0.10 mA·cm-2 to 0.49 mA·cm-2).",Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33620010/),[μg] / [(cm)^2·h],304.93,75021,DB00457,Prazosin
,33620010,AUC0-t,"The main pharmacokinetic parameters of the high current group (0.17 mA·cm-2) and the low current group (0.09 mA·cm-2) were AUC0-t: 5873.0 ng·mL-1·h and 2493.7 ng·mL-1·h, respectively.",Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33620010/),[h·ng] / [ml],5873.0,75022,DB00457,Prazosin
,33620010,AUC0-t,"The main pharmacokinetic parameters of the high current group (0.17 mA·cm-2) and the low current group (0.09 mA·cm-2) were AUC0-t: 5873.0 ng·mL-1·h and 2493.7 ng·mL-1·h, respectively.",Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33620010/),[h·ng] / [ml],2493.7,75023,DB00457,Prazosin
,7295470,elimination half-life,2 The elimination half-life (min) of prazosin was 123 +/- 19.4 (s.d.) in the young and 194 +/- 36 in the elderly (P less than 0.01).,Prazosin disposition in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),min,123,75170,DB00457,Prazosin
,7295470,elimination half-life,2 The elimination half-life (min) of prazosin was 123 +/- 19.4 (s.d.) in the young and 194 +/- 36 in the elderly (P less than 0.01).,Prazosin disposition in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),min,194,75171,DB00457,Prazosin
,7295470,Clearance,3 Clearance (ml min-1 kg-1) was 3.94 +/- 0.73 in the young and 3.53 +/- 1 in the elderly (P greater than 0.1).,Prazosin disposition in young and elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),[ml] / [kg·min],3.94,75172,DB00457,Prazosin
,7295470,Clearance,3 Clearance (ml min-1 kg-1) was 3.94 +/- 0.73 in the young and 3.53 +/- 1 in the elderly (P greater than 0.1).,Prazosin disposition in young and elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),[ml] / [kg·min],3.53,75173,DB00457,Prazosin
,7295470,Volume of distribution at steady state,Volume of distribution at steady state (1 kg-1) was 0.63 +/- 0.14 in the young and 0.89 +/- 0.26 in the elderly (P less than 0.05).,Prazosin disposition in young and elderly subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),[1] / [kg],0.63,75174,DB00457,Prazosin
,7295470,Volume of distribution at steady state,Volume of distribution at steady state (1 kg-1) was 0.63 +/- 0.14 in the young and 0.89 +/- 0.26 in the elderly (P less than 0.05).,Prazosin disposition in young and elderly subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),[1] / [kg],0.89,75175,DB00457,Prazosin
,7295470,absolute bioavailability,4 The absolute bioavailability of orally administered prazosin was 0.68 +/- 0.17 in the young and 0.48 +/- 0.16 in the elderly (P less than 0.05).,Prazosin disposition in young and elderly subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),,0.68,75176,DB00457,Prazosin
,7295470,absolute bioavailability,4 The absolute bioavailability of orally administered prazosin was 0.68 +/- 0.17 in the young and 0.48 +/- 0.16 in the elderly (P less than 0.05).,Prazosin disposition in young and elderly subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295470/),,0.48,75177,DB00457,Prazosin
,8739810,serum t1/2,The serum t1/2 in the elderly was 210 min while in the young group was 139 min.,The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739810/),min,210,75385,DB00457,Prazosin
,8739810,serum t1/2,The serum t1/2 in the elderly was 210 min while in the young group was 139 min.,The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739810/),min,139,75386,DB00457,Prazosin
,8739810,time to Cmax,"The Cmax was identical in the two groups, and the time to Cmax was 84 min in the elderly and 114 min in the young subjects.",The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739810/),min,84,75387,DB00457,Prazosin
,8739810,time to Cmax,"The Cmax was identical in the two groups, and the time to Cmax was 84 min in the elderly and 114 min in the young subjects.",The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739810/),min,114,75388,DB00457,Prazosin
,8739810,Protein binding,Protein binding was 93.4% in the elderly and 93.5% in the young subjects and the serum alpha 1 acid glycoprotein concentration was not different in the two groups of subjects.,The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739810/),%,93.4,75389,DB00457,Prazosin
,8739810,Protein binding,Protein binding was 93.4% in the elderly and 93.5% in the young subjects and the serum alpha 1 acid glycoprotein concentration was not different in the two groups of subjects.,The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739810/),%,93.5,75390,DB00457,Prazosin
,1971750,binding affinity constant (Ki),"Naftopidil could be characterized by receptor binding studies as an alpha 1-adrenergic antagonist with a binding affinity constant (Ki) of 58.3 nmol/l. both enantiomers of naftopidil revealed similar values, indicating no stereoselective inhibition of 3H-prazosin-binding.",Radioreceptor assay for the determination of alpha 1-adrenoceptor-binding material in rat plasma following single oral administration of naftopidil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971750/),[nM] / [l],58.3,78923,DB00457,Prazosin
,1971750,Terminal half-life,Terminal half-life was calculated with 16.7 h.,Radioreceptor assay for the determination of alpha 1-adrenoceptor-binding material in rat plasma following single oral administration of naftopidil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971750/),h,16.7,78924,DB00457,Prazosin
,2968267,plasma elimination half-life,The plasma elimination half-life during the dose interval in these patients was 16.1 h (range 10.1-27.1 h) and the median time to peak plasma concentration was 3 h (range 1-4 h).,A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968267/),h,16.1,95665,DB00457,Prazosin
,2968267,time to peak plasma concentration,The plasma elimination half-life during the dose interval in these patients was 16.1 h (range 10.1-27.1 h) and the median time to peak plasma concentration was 3 h (range 1-4 h).,A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968267/),h,3,95666,DB00457,Prazosin
,1348752,plasma half-life,"Doxazosin, an alpha-adrenergic blocking agent, has a plasma half-life in male rats of 1-2 h after i.v. administration.",Diurnal exposure profile in rats from dietary administration of a chemical (doxazosin) with a short half-life: interplay of age and diurnal feeding pattern. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348752/),h,1-2,95911,DB00457,Prazosin
,16411525,CrCl,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [·1.73·m2·week],51.3,101575,DB00457,Prazosin
,16411525,CrCl,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [·1.73·m2·week],45.8,101576,DB00457,Prazosin
,16411525,Kt/V urea,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),,1.75,101577,DB00457,Prazosin
,16411525,Kt/V urea,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),,1.59,101578,DB00457,Prazosin
,16411525,drained dialysate volume,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [d],8.80,101579,DB00457,Prazosin
,16411525,drained dialysate volume,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [d],8.44,101580,DB00457,Prazosin
,6123342,elimination half-life,5 The mean elimination half-life of doxazosin was 11 h.,"A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123342/),h,11,109337,DB00457,Prazosin
,6123342,T1/2,This compared with a T1/2 of 2.5 h for prazosin.,"A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123342/),h,2.5,109338,DB00457,Prazosin
,7767316,half-life,"The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7% ID/g) at 5 min, followed by clearance with a half-life of 16.1 min.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),min,16.1,112974,DB00457,Prazosin
,7767316,ratio,"As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),,7.4,112975,DB00457,Prazosin
,7767316,ED50,[11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum.,[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),[mg] / [kg],0.3,112976,DB00457,Prazosin
>,33429127,recovery,The recovery of analyte was >98% and IS >94%.,Simple and fast LC-MS/MS method for quantification of terazosin in human plasma and application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429127/),%,98,115049,DB00457,Prazosin
>,33429127,recovery,The recovery of analyte was >98% and IS >94%.,Simple and fast LC-MS/MS method for quantification of terazosin in human plasma and application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429127/),%,94,115050,DB00457,Prazosin
,9933049,peak,"Clinical response to doxazosin plateaued at peak and trough plasma concentrations of between 60 and 80 ng/mL and 25 ng/mL, respectively, corresponding to a dose of 8 mg daily.",Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9933049/),[ng] / [ml],60 and 80,117660,DB00457,Prazosin
,9933049,trough plasma concentrations,"Clinical response to doxazosin plateaued at peak and trough plasma concentrations of between 60 and 80 ng/mL and 25 ng/mL, respectively, corresponding to a dose of 8 mg daily.",Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9933049/),[ng] / [ml],25,117661,DB00457,Prazosin
,9933049,maximal therapeutic dosage,The maximal therapeutic dosage of doxazosin would appear to be 8 mg in this group of BPH patients.,Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9933049/),mg,8,117662,DB00457,Prazosin
,26205661,maximum plasma concentration (Cmax ),"The maximum plasma concentration (Cmax ) value of (-)-(R)-doxazosin after oral administration was significantly higher when given alone (110.5 ± 46.4 ng/mL) versus in racemate (53.2 ± 19.7 ng/mL), whereas the Cmax value of (+)-(S)-doxazosin did not change significantly.",Enantioselective pharmacokinetics of doxazosin and pharmacokinetic interaction between the isomers in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26205661/),[ng] / [ml],110.5,118584,DB00457,Prazosin
,26205661,maximum plasma concentration (Cmax ),"The maximum plasma concentration (Cmax ) value of (-)-(R)-doxazosin after oral administration was significantly higher when given alone (110.5 ± 46.4 ng/mL) versus in racemate (53.2 ± 19.7 ng/mL), whereas the Cmax value of (+)-(S)-doxazosin did not change significantly.",Enantioselective pharmacokinetics of doxazosin and pharmacokinetic interaction between the isomers in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26205661/),[ng] / [ml],53.2,118585,DB00457,Prazosin
,2939868,half-life,"Pharmacokinetics of doxazosin, measured at steady state in 36 patients, showed dose-related plasma concentrations, a mean half-life of about 12 h and relatively low intersubject variation.",A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939868/),h,12,120031,DB00457,Prazosin
>,19373887,IC(50),"CP-100,356 was devoid of inhibition (IC(50) >50 microM) against major human P450 enzymes including P4503A4.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,50,121222,DB00457,Prazosin
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,0.5,121223,DB00457,Prazosin
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.2,121224,DB00457,Prazosin
,19373887,IC(50),"Inhibition of prazosin transport (IC(50) approximately 1.5 +/- 0.3 microM) in human BCRP-transfected MDCKII cells by CP-100,356 confirmed the dual MDR1/BCRP inhibitory properties.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.5,121225,DB00457,Prazosin
,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,66,121226,DB00457,Prazosin
>,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,15,121227,DB00457,Prazosin
,2939865,Plasma protein binding,"Plasma protein binding was high in all species studied, ranging from 95.3% in the rat to 98.3% in human patients.","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),%,95.3,124313,DB00457,Prazosin
,2939865,Plasma protein binding,"Plasma protein binding was high in all species studied, ranging from 95.3% in the rat to 98.3% in human patients.","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),%,98.3,124314,DB00457,Prazosin
,2939865,Oral bioavailability,"Oral bioavailability is 60% in dog and approximately 50% in the rat, which is similar to the value of 63% reported for man at therapeutic doses.","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),%,60,124315,DB00457,Prazosin
,2939865,Oral bioavailability,"Oral bioavailability is 60% in dog and approximately 50% in the rat, which is similar to the value of 63% reported for man at therapeutic doses.","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),%,50,124316,DB00457,Prazosin
,2939865,Oral bioavailability,"Oral bioavailability is 60% in dog and approximately 50% in the rat, which is similar to the value of 63% reported for man at therapeutic doses.","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),%,63,124317,DB00457,Prazosin
,2939865,plasma clearance,"Mean plasma clearance values were 13 ml min-1 kg-1 (dogs), 30 ml min-1 kg-1 (rats) and 1.2 ml min-1 kg-1 (human subjects).","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),[ml] / [kg·min],13,124318,DB00457,Prazosin
,2939865,plasma clearance,"Mean plasma clearance values were 13 ml min-1 kg-1 (dogs), 30 ml min-1 kg-1 (rats) and 1.2 ml min-1 kg-1 (human subjects).","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),[ml] / [kg·min],30,124319,DB00457,Prazosin
,2939865,plasma clearance,"Mean plasma clearance values were 13 ml min-1 kg-1 (dogs), 30 ml min-1 kg-1 (rats) and 1.2 ml min-1 kg-1 (human subjects).","The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),[ml] / [kg·min],1.2,124320,DB00457,Prazosin
,2939865,plasma half-life,Mean plasma half-life values were 5 h in dogs and 1.2 h in rats: a value of 9 h was reported for human volunteers (cf. 2.5 h for prazosin).,"The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),h,5,124321,DB00457,Prazosin
,2939865,plasma half-life,Mean plasma half-life values were 5 h in dogs and 1.2 h in rats: a value of 9 h was reported for human volunteers (cf. 2.5 h for prazosin).,"The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),h,1.2,124322,DB00457,Prazosin
,2939865,plasma half-life,Mean plasma half-life values were 5 h in dogs and 1.2 h in rats: a value of 9 h was reported for human volunteers (cf. 2.5 h for prazosin).,"The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),h,9,124323,DB00457,Prazosin
,2939865,plasma half-life,Mean plasma half-life values were 5 h in dogs and 1.2 h in rats: a value of 9 h was reported for human volunteers (cf. 2.5 h for prazosin).,"The metabolism and kinetics of doxazosin in man, mouse, rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939865/),h,2.5,124324,DB00457,Prazosin
greater,11043762,Recovery,Recovery values were all greater than 90% over the concentration range 0.25-100 ng/ml.,Improved high-performance liquid chromatographic analysis of terazosin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043762/),%,90,125514,DB00457,Prazosin
,1317234,receptor occupancy,"In the alpha 1-radioreceptor assay, plasma concentrations from 0.9- to 1.7-fold the equilibrium dissociation constant (Ki) of carvedilol could be evaluated 1 as well as 3.5 h after medication, corresponding with a receptor occupancy of 44%-63%.",Oral administration of carvedilol and prazosin inhibits the prostaglandin F2 alpha- and noradrenaline-induced contraction of human hand veins in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317234/),%,44,125985,DB00457,Prazosin
,7389255,terminal half-life t1/2,Prazosin disappeared from plasma with a terminal half-life t1/2 of about 3 hr and had a central distribution volume of about 0.18 1/kg.,Prazosin kinetics in essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389255/),h,3,132368,DB00457,Prazosin
,7389255,central distribution volume,Prazosin disappeared from plasma with a terminal half-life t1/2 of about 3 hr and had a central distribution volume of about 0.18 1/kg.,Prazosin kinetics in essential hypertension. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389255/),[1] / [kg],0.18,132369,DB00457,Prazosin
,7389255,t1/2,Absorption kinetics were apparently linear with a t1/2 of about 30 min.,Prazosin kinetics in essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389255/),min,30,132370,DB00457,Prazosin
,1678920,half-life,The relatively long half-life of terazosin (12 hours) enables it to be administered in a once-a-day regimen.,Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1678920/),h,12,134292,DB00457,Prazosin
,24291719,flow rate,"The HPLC separation was performed on a CAPCELL PAK SCX column (250mm×4.6mm, 5.0μm, Shiseido, Japan) with a mobile phase of acetonitrile/80mmol/L ammonium phosphate (pH adjusted to 6.0) (60:40, v/v) at a flow rate of 1.2mL/min.",Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291719/),[ml] / [min],1.2,136669,DB00457,Prazosin
,24291719,extraction recovery,The extraction recovery was 72.6-88.3% and the method was over the concentration range of 5.0-2486ng/mL with a lower limit of quantitation (LLOQ) of 5.0ng/mL using 300μL of plasma.,Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291719/),%,72.6-88.3,136670,DB00457,Prazosin
,4011659,relative bioavailability,"Compared to the Minipress, the relative bioavailability of the preparation Adversuten was calculated to 102%.",[Comparative study of the relative bioavailabilities of two prazosin preparations in patients with essential hypertension]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4011659/),%,102,140470,DB00457,Prazosin
more,16235201,absolute recoveries,The absolute recoveries of doxazosin and prazosin from human plasma were more than 91%.,Validation and pharmacokinetic application of a method for determination of doxazosin in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16235201/),%,91,142661,DB00457,Prazosin
,3801655,elimination half-life,"Prazosin level in this phase decreased, its elimination half-life being about 9 hours, while the metabolite serum level was almost constant between 4 and 24 hours and averaged 0.9 mumol/l.",[Slow elimination of a prazosin metabolite compared to prazosin kinetics after its intravenous administration to rabbits]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3801655/),h,9,148385,DB00457,Prazosin
,2945688,elimination t1/2,The mean (SE) elimination t1/2 was 12.6 hours (3.3) in the volunteers and 13.3 hours (1.8) in the patients with renal insufficiency (not significant).,Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2945688/),h,12.6,148470,DB00457,Prazosin
,2945688,elimination t1/2,The mean (SE) elimination t1/2 was 12.6 hours (3.3) in the volunteers and 13.3 hours (1.8) in the patients with renal insufficiency (not significant).,Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2945688/),h,13.3,148471,DB00457,Prazosin
,2872802,volume of distribution,"Approximately 90 to 94 percent of the drug is bound to plasma proteins, with the volume of distribution estimated to be 25 to 30 liters.",Pharmacokinetics of terazosin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),l,25 to 30,149425,DB00457,Prazosin
,2872802,Plasma,"Plasma and renal clearances are 80 and 10 ml per minute, respectively.",Pharmacokinetics of terazosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),[ml] / [min],80,149426,DB00457,Prazosin
,2872802,renal clearances,"Plasma and renal clearances are 80 and 10 ml per minute, respectively.",Pharmacokinetics of terazosin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),[ml] / [min],10,149427,DB00457,Prazosin
,2872802,beta-phase half-life,The mean beta-phase half-life is approximately 12 hours.,Pharmacokinetics of terazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),h,12,149428,DB00457,Prazosin
,6135439,terminal elimination half-life,The terminal elimination half-life following oral and intravenous doxazosin was about 9 h.,"Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135439/),h,9,153105,DB00457,Prazosin
,2591463,tmax,"After 1 and 5 mg, tmax ranged from 1-2 h; Cmax (4.1 to 20.8 ng.ml-1; AUC (0-24) 20 to 132 ng.",Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591463/),h,1-2,155235,DB00457,Prazosin
,2591463,Cmax,"After 1 and 5 mg, tmax ranged from 1-2 h; Cmax (4.1 to 20.8 ng.ml-1; AUC (0-24) 20 to 132 ng.",Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591463/),[ng] / [ml],4.1 to 20.8,155236,DB00457,Prazosin
,2591463,AUC (0-24),"After 1 and 5 mg, tmax ranged from 1-2 h; Cmax (4.1 to 20.8 ng.ml-1; AUC (0-24) 20 to 132 ng.",Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591463/),ng,20 to 132,155237,DB00457,Prazosin
,18266399,E(max),"For systolic blood pressure, E(max) was 29.9 +/- 10.6 mmHg.",Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18266399/),mmhg,29.9,156465,DB00457,Prazosin
,18266399,first-order rate constant,The obtained first-order rate constant values (0.40 +/- 0.006 h(-)(1) for systolic blood pressure and 0.47 +/- 0.012 h(-)(1) for diastolic blood pressure) were consistent with the rapid development of pharmacological effect.,Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18266399/),h(-)(1),0.40,156466,DB00457,Prazosin
,18266399,first-order rate constant,The obtained first-order rate constant values (0.40 +/- 0.006 h(-)(1) for systolic blood pressure and 0.47 +/- 0.012 h(-)(1) for diastolic blood pressure) were consistent with the rapid development of pharmacological effect.,Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18266399/),h(-)(1),0.47,156467,DB00457,Prazosin
,18266399,EC(50),EC(50) (concentration of terazosin that induces an effect at 50% of E(max) values) values were similar for systolic (29.9 +/- 4.3 microg/L) and diastolic (28.7 +/- 4.0 microg/L) blood pressure.,Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18266399/),[μg] / [l],29.9,156468,DB00457,Prazosin
,18266399,EC(50),EC(50) (concentration of terazosin that induces an effect at 50% of E(max) values) values were similar for systolic (29.9 +/- 4.3 microg/L) and diastolic (28.7 +/- 4.0 microg/L) blood pressure.,Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18266399/),[μg] / [l],28.7,156469,DB00457,Prazosin
,21340,plasma half-life,The plasma half-life in normal volunteers was 3-8 hours but in some patients it seems to be considerably longer.,Use of prazosin at the dunedin hypertension clinic controlled and open studies and pharmacokinetic observations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21340/),h,3-8,158292,DB00457,Prazosin
,2951261,plasma half-life,Mean plasma concentrations of doxazosin were proportional to dose and the plasma half-life was 11.5 h and independent of dose.,The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951261/),h,11.5,166854,DB00457,Prazosin
,23624508,flow rate,"Both compounds were extracted from dog plasma with ethyl acetate and were separated by HPLC on a reversed phase C₁₈ column with a mobile phase of 10 mM ammonium acetate buffer containing 0.1% formic acid-acetonitrile (40:60, v/v) at a flow rate of 0.2 mL/min.","Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624508/),[ml] / [min],0.2,168406,DB00457,Prazosin
,23624508,m/z,"The monitored transitions were m/z 425.3 → 309.2 for tafetinib, m/z 397.2 → 309.2 for M1 and m/z 384.2 → 247.1 for IS.","Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624508/),,425.3,168407,DB00457,Prazosin
,23624508,m/z,"The monitored transitions were m/z 425.3 → 309.2 for tafetinib, m/z 397.2 → 309.2 for M1 and m/z 384.2 → 247.1 for IS.","Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624508/),,309.2,168408,DB00457,Prazosin
,23624508,m/z,"The monitored transitions were m/z 425.3 → 309.2 for tafetinib, m/z 397.2 → 309.2 for M1 and m/z 384.2 → 247.1 for IS.","Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624508/),,397.2,168409,DB00457,Prazosin
,23624508,m/z,"The monitored transitions were m/z 425.3 → 309.2 for tafetinib, m/z 397.2 → 309.2 for M1 and m/z 384.2 → 247.1 for IS.","Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624508/),,384.2,168410,DB00457,Prazosin
,23624508,m/z,"The monitored transitions were m/z 425.3 → 309.2 for tafetinib, m/z 397.2 → 309.2 for M1 and m/z 384.2 → 247.1 for IS.","Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624508/),,247.1,168411,DB00457,Prazosin
,23624508,run time,The developed method had a short run time of 4 min and good linearity was observed over a wide range of 1-1000 ng/mL for the two compounds.,"Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624508/),,4,168412,DB00457,Prazosin
,6840172,peak level (Cmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],29.1,178034,DB00457,Prazosin
,6840172,Tmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,1.3,178035,DB00457,Prazosin
,6840172,total area under the serum concentration-time curve (AUC0-infinity),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[h·ng] / [ml],154.4,178036,DB00457,Prazosin
,6840172,total clearance (Cltot),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],751.5,178037,DB00457,Prazosin
,6840172,renal clearance (Clren),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],97.2,178038,DB00457,Prazosin
,6840172,elimination half-life (t1/2),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,2.9,178039,DB00457,Prazosin
,6840172,Cmax,"Dihydralazine enhanced Cmax (38.2 +/- 4.6 ng/ml) only when compared to phenobarbitone treatment, and did not affect any other parameters.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],38.2,178040,DB00457,Prazosin
,6840172,Cmax,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],25.5,178041,DB00457,Prazosin
,6840172,AUC0-infinity,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),,117.5,178042,DB00457,Prazosin
,6840172,Cltot,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],957.5,178043,DB00457,Prazosin
,10594469,relative bioavailability,The relative bioavailability of doxazosin GITS is approximately 60%.,Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594469/),%,60,181023,DB00457,Prazosin
,2975595,Cmax at steady-state,For an 8 mg daily dose mean Cmax at steady-state for all patients was 108 ng/ml; the mean tmax was 1.8 h.,Doxazosin in patients with hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2975595/),[ng] / [ml],108,181198,DB00457,Prazosin
,2975595,tmax,For an 8 mg daily dose mean Cmax at steady-state for all patients was 108 ng/ml; the mean tmax was 1.8 h.,Doxazosin in patients with hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2975595/),h,1.8,181199,DB00457,Prazosin
,2975595,terminal elimination half-life,The mean terminal elimination half-life was 22 h.,Doxazosin in patients with hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2975595/),h,22,181200,DB00457,Prazosin
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,4.3,188010,DB00457,Prazosin
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,3.6,188011,DB00457,Prazosin
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,1.9,188012,DB00457,Prazosin
,30884977,mean residence time,The in vivo pharmacokinetic results indicated the enhancement in bioavailability of DM by 7 folds compared to drug suspension and the mean residence time prolonged to 23.72 h compared to 4.7 h of drug suspension.,"Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: in vitro, and in vivo evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30884977/),h,23.72,188112,DB00457,Prazosin
,30884977,mean residence time,The in vivo pharmacokinetic results indicated the enhancement in bioavailability of DM by 7 folds compared to drug suspension and the mean residence time prolonged to 23.72 h compared to 4.7 h of drug suspension.,"Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: in vitro, and in vivo evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30884977/),h,4.7,188113,DB00457,Prazosin
,22887707,R/S ratio of AUC(0-∞),The R/S ratio of AUC(0-∞) of terazosin was 1.68.,Pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22887707/),,1.68,191400,DB00457,Prazosin
,20189472,recovery,"The recovery was 67.8-83.1%, and the limit of quantitation (LOQ) detection was 0.78 ng mL(-1) for metoclopramide.",Determination of metoclopramide in human plasma by LC-ESI-MS and its application to bioequivalance studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20189472/),%,67.8-83.1,193352,DB00457,Prazosin
,6994981,time of peak concentration,"In normal healthy volunteers, the time of peak concentration occurs between 1 and 3 hours after oral administration, with wide interindividual variations.",Clinical pharmacokinetics of prazosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994981/),h,1 and 3,198576,DB00457,Prazosin
,6994981,Oral bioavailability,Oral bioavailability of prazosin ranges from 43.5 to 69.3% (mean 56.9%).,Clinical pharmacokinetics of prazosin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994981/),%,56.9,198577,DB00457,Prazosin
,6994981,elimination half-life,The mean elimination half-life is about 2.5 hours.,Clinical pharmacokinetics of prazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994981/),h,2.5,198578,DB00457,Prazosin
,6994981,steady-state volume of distribution,"After intravenous administration, the steady-state volume of distribution has been calculated to be 42.2 +/- 8.9L and the total body clearance 12.7 +/- 1.3L/h.",Clinical pharmacokinetics of prazosin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994981/),l,42.2,198579,DB00457,Prazosin
,6994981,total body clearance,"After intravenous administration, the steady-state volume of distribution has been calculated to be 42.2 +/- 8.9L and the total body clearance 12.7 +/- 1.3L/h.",Clinical pharmacokinetics of prazosin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6994981/),[l] / [h],12.7,198580,DB00457,Prazosin
,23439864,area under the concentration-time curve (AUC0-18 hours) ratio,The milk/plasma area under the concentration-time curve (AUC0-18 hours) ratio was 0.1.,Transfer of doxazosin into breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23439864/),,0.1,200710,DB00457,Prazosin
,23439864,maximum milk concentrations,The average and maximum milk concentrations were 2.9 and 4.2 µg/L.,Transfer of doxazosin into breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23439864/),[μg] / [l],4.2,200711,DB00457,Prazosin
,2895548,elimination half-life,"The parameters derived were in good agreement with a mean elimination half-life of 539 +/- 75 min, bioavailability of 0.65 +/- 0.11 and clearance of 140 +/- 26 ml/min.",Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895548/),min,539,200734,DB00457,Prazosin
,2895548,bioavailability,"The parameters derived were in good agreement with a mean elimination half-life of 539 +/- 75 min, bioavailability of 0.65 +/- 0.11 and clearance of 140 +/- 26 ml/min.",Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895548/),,0.65,200735,DB00457,Prazosin
,2895548,clearance,"The parameters derived were in good agreement with a mean elimination half-life of 539 +/- 75 min, bioavailability of 0.65 +/- 0.11 and clearance of 140 +/- 26 ml/min.",Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895548/),[ml] / [min],140,200736,DB00457,Prazosin
,6166804,Time of maximum plasma concentration,Time of maximum plasma concentration (2 hr) and half-life in plasma (5.6 hr) were similar after all four doses.,Pharmacokinetic and pharmacodynamic studies with prazosin in chronic heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166804/),h,2,202085,DB00457,Prazosin
,6166804,half-life,Time of maximum plasma concentration (2 hr) and half-life in plasma (5.6 hr) were similar after all four doses.,Pharmacokinetic and pharmacodynamic studies with prazosin in chronic heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166804/),h,5.6,202086,DB00457,Prazosin
,94630,bioavailability,The bioavailability of prazosin was 0.38 +/- 0.11.,Prazosin first-pass metabolism and hepatic extraction in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94630/),,0.38,208992,DB00457,Prazosin
,94630,hepatic extraction,In anesthetized dogs the hepatic extraction of prazosin was 0.47 +/- 0.08 for a predicted availability of 0.53 +/- 0.08.,Prazosin first-pass metabolism and hepatic extraction in the dog. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94630/),,0.47,208993,DB00457,Prazosin
,94630,availability,In anesthetized dogs the hepatic extraction of prazosin was 0.47 +/- 0.08 for a predicted availability of 0.53 +/- 0.08.,Prazosin first-pass metabolism and hepatic extraction in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94630/),,0.53,208994,DB00457,Prazosin
,94630,half-life,"Following intravenous administration to conscious dogs, prazosin concentrations in whole blood declined with a fast half-life of 3.9 +/- 1.74 min and a slow half-life of 153 +/- 24 min, the volume of distribution at steady state being 48.6 +/- 15.3 liters in dogs (mean weight, 22.6 kg).",Prazosin first-pass metabolism and hepatic extraction in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94630/),min,3.9,208995,DB00457,Prazosin
,94630,half-life,"Following intravenous administration to conscious dogs, prazosin concentrations in whole blood declined with a fast half-life of 3.9 +/- 1.74 min and a slow half-life of 153 +/- 24 min, the volume of distribution at steady state being 48.6 +/- 15.3 liters in dogs (mean weight, 22.6 kg).",Prazosin first-pass metabolism and hepatic extraction in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94630/),min,153,208996,DB00457,Prazosin
,94630,volume of distribution at steady state,"Following intravenous administration to conscious dogs, prazosin concentrations in whole blood declined with a fast half-life of 3.9 +/- 1.74 min and a slow half-life of 153 +/- 24 min, the volume of distribution at steady state being 48.6 +/- 15.3 liters in dogs (mean weight, 22.6 kg).",Prazosin first-pass metabolism and hepatic extraction in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94630/),l,48.6,208997,DB00457,Prazosin
,2540317,elimination half-life,"The drug reached maximal concentrations in plasma and brain within 10 to 30 min of injection (2 mg/kg) with an elimination half-life of 1.9 and 2.05 hr, respectively.",Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540317/),h,1.9,210789,DB00457,Prazosin
,2540317,elimination half-life,"The drug reached maximal concentrations in plasma and brain within 10 to 30 min of injection (2 mg/kg) with an elimination half-life of 1.9 and 2.05 hr, respectively.",Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540317/),h,2.05,210790,DB00457,Prazosin
,2540317,blood-to-plasma ratio,MK-801 distributed almost equally between plasma and red cells (mean blood-to-plasma ratio averaged 1.2 +/- 0.2 when calculated 30 and 180 min from drug administration).,Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540317/),,1.2,210791,DB00457,Prazosin
,2540317,brain-to-plasma ratio,Plasma and brain concentrations of MK-801 rose almost linearly from 0.5 to 4 mg/kg 30 min after injection and the brain-to-plasma ratio (12.9 +/- 2.8) was constant in the dose range studied.,Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540317/),,12.9,210792,DB00457,Prazosin
,7438656,lag time,"On average, the lag time was 0.650 and 0.448 hours, and the elimination half-life 2.3 and 2.5 hours, for the 0.5 and 1.5mg doses, respectively.",Pharmacokinetics of prazosin in normotensive subjects after low oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438656/),h,0.650,213576,DB00457,Prazosin
,7438656,lag time,"On average, the lag time was 0.650 and 0.448 hours, and the elimination half-life 2.3 and 2.5 hours, for the 0.5 and 1.5mg doses, respectively.",Pharmacokinetics of prazosin in normotensive subjects after low oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438656/),h,0.448,213577,DB00457,Prazosin
,7438656,elimination half-life,"On average, the lag time was 0.650 and 0.448 hours, and the elimination half-life 2.3 and 2.5 hours, for the 0.5 and 1.5mg doses, respectively.",Pharmacokinetics of prazosin in normotensive subjects after low oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438656/),h,2.3,213578,DB00457,Prazosin
,7438656,elimination half-life,"On average, the lag time was 0.650 and 0.448 hours, and the elimination half-life 2.3 and 2.5 hours, for the 0.5 and 1.5mg doses, respectively.",Pharmacokinetics of prazosin in normotensive subjects after low oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438656/),h,2.5,213579,DB00457,Prazosin
,690251,half-life,Drug leaves plasma with a half-life of approximately 2.3 hours.,Pharmacokinetics of prazosin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/690251/),h,2.3,213681,DB00457,Prazosin
,8351678,Relative bioavailability,Relative bioavailability of prazosin administered as GITS was only 49.4 +/- 19.5% (B) and 45.5 +/- 18.7 (C) versus 73.8 +/- 13.9% (D) (area under the curve normalized at 3 mg dosing); but absorption was sustained and plasma concentrations were maintained at a virtually constant level for a time period close to 24 h.,Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351678/),%,49.4,216000,DB00457,Prazosin
,8351678,Relative bioavailability,Relative bioavailability of prazosin administered as GITS was only 49.4 +/- 19.5% (B) and 45.5 +/- 18.7 (C) versus 73.8 +/- 13.9% (D) (area under the curve normalized at 3 mg dosing); but absorption was sustained and plasma concentrations were maintained at a virtually constant level for a time period close to 24 h.,Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351678/),%,45.5,216001,DB00457,Prazosin
,8351678,Relative bioavailability,Relative bioavailability of prazosin administered as GITS was only 49.4 +/- 19.5% (B) and 45.5 +/- 18.7 (C) versus 73.8 +/- 13.9% (D) (area under the curve normalized at 3 mg dosing); but absorption was sustained and plasma concentrations were maintained at a virtually constant level for a time period close to 24 h.,Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351678/),%,73.8,216002,DB00457,Prazosin
,8351678,mean residence time (MRT),"As a result, mean residence time (MRT) of prazosin was considerably increased after GITS administration: 21.6 +/- 1.0 h (B), 22.5 +/- 1.6 h (C) instead of 5.9 +/- 0.2 h for the reference formulation (A) and 10.8 +/- 0.8 h for the traditional sustained release formulation (D).",Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351678/),h,21.6,216003,DB00457,Prazosin
,8351678,mean residence time (MRT),"As a result, mean residence time (MRT) of prazosin was considerably increased after GITS administration: 21.6 +/- 1.0 h (B), 22.5 +/- 1.6 h (C) instead of 5.9 +/- 0.2 h for the reference formulation (A) and 10.8 +/- 0.8 h for the traditional sustained release formulation (D).",Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351678/),h,22.5,216004,DB00457,Prazosin
,8351678,mean residence time (MRT),"As a result, mean residence time (MRT) of prazosin was considerably increased after GITS administration: 21.6 +/- 1.0 h (B), 22.5 +/- 1.6 h (C) instead of 5.9 +/- 0.2 h for the reference formulation (A) and 10.8 +/- 0.8 h for the traditional sustained release formulation (D).",Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351678/),h,5.9,216005,DB00457,Prazosin
,8351678,mean residence time (MRT),"As a result, mean residence time (MRT) of prazosin was considerably increased after GITS administration: 21.6 +/- 1.0 h (B), 22.5 +/- 1.6 h (C) instead of 5.9 +/- 0.2 h for the reference formulation (A) and 10.8 +/- 0.8 h for the traditional sustained release formulation (D).",Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351678/),h,10.8,216006,DB00457,Prazosin
,18401863,LOQ,The LOQ for doxazosin was 0.2 ng/mL using 100 microL plasma sample.,Quantification of doxazosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401863/),[ng] / [ml],0.2,217179,DB00457,Prazosin
,18401863,recoveries,"The recoveries of doxazosin and cisapride were 67.4 and 61.7%, respectively.",Quantification of doxazosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401863/),%,67.4,217180,DB00457,Prazosin
,18401863,recoveries,"The recoveries of doxazosin and cisapride were 67.4 and 61.7%, respectively.",Quantification of doxazosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401863/),%,61.7,217181,DB00457,Prazosin
,2599083,half-life,The increase of the half-life of the drug (6.6 +/- 1.6 h) and the elevation of the blood plasma concentration 1-2.5 h after administration (87 +/- 33 ng/ml) were found.,[The pharmacokinetics and the concentration-and-effect relationship of prazosin in patients at the beginning of the subacute period of myocardial infarct complicated by the development of heart failure]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2599083/),h,6.6,220138,DB00457,Prazosin
,17729099,flow rate,"A reversed phase C18 column was used for the separation of doxazosin and prazosin (internal standard) with a mobile phase composed of water, acetonitrile, triethylamine (68:32:0.2 v/v, pH 5.0) at a flow rate of 1.2 mL/min.",Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17729099/),[ml] / [min],1.2,224728,DB00457,Prazosin
greater,17729099,Recovery,Recovery of doxazosin from human plasma was greater than 93.4%.,Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17729099/),%,93.4,224729,DB00457,Prazosin
,17729099,area under the curve,"At steady state the mean area under the curve for a dosing interval and elimination half-life were calculated to be 367.0 +/- 63.5 ng x hr/mL and 29.2 +/- 4.5 hr, respectively.",Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17729099/),[h·ng] / [ml],367.0,224730,DB00457,Prazosin
,17729099,elimination half-life,"At steady state the mean area under the curve for a dosing interval and elimination half-life were calculated to be 367.0 +/- 63.5 ng x hr/mL and 29.2 +/- 4.5 hr, respectively.",Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17729099/),h,29.2,224731,DB00457,Prazosin
,26116989,depletion rate constant (kdep),We found that the plasma levels of the (-)-isomer were significantly lower than those of the (+)-enantiomer following i.v. administration of (±)-DOX to the rats and that the depletion rate constant (kdep) of (-)-DOX (0.0107±0.0007L/min) was significantly larger than that of (+)-DOX (kdep 0.0088±0.0005L/min) (p<0.05) when (±)-DOX was incubated with rat liver microsomes (RLMs).,The truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116989/),[l] / [min],0.0107,226014,DB00457,Prazosin
,26116989,kdep,We found that the plasma levels of the (-)-isomer were significantly lower than those of the (+)-enantiomer following i.v. administration of (±)-DOX to the rats and that the depletion rate constant (kdep) of (-)-DOX (0.0107±0.0007L/min) was significantly larger than that of (+)-DOX (kdep 0.0088±0.0005L/min) (p<0.05) when (±)-DOX was incubated with rat liver microsomes (RLMs).,The truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116989/),[l] / [min],0.0088,226015,DB00457,Prazosin
,6713738,systemic vascular resistance,"Administration of prazosin induced significant decreases in mean pulmonary capillary wedge pressure (from 27.5, s.e.m. = 4.5 to 19.4, s.e.m. = 5.1 mmHg; P less than 0.001), mean arterial blood pressure (from 94.5, s.e.m. = 6.0 to 85.4, s.e.m. = 5.0 mmHg; P less than 0.01), and systemic vascular resistance (from 1690, s.e.m. = 360 to 1420, s.e.m. = 200 dyn. s/cm5; P less than 0.05) and a rise in cardiac index from 1.98 (s.e.m. = 0.07) to 2.28 (s.e.m. = 0.16) litres/min per m2 (P less than 0.05).",Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713738/),[dyn·s] / [cm5],1690,236121,DB00457,Prazosin
,6713738,systemic vascular resistance,"Administration of prazosin induced significant decreases in mean pulmonary capillary wedge pressure (from 27.5, s.e.m. = 4.5 to 19.4, s.e.m. = 5.1 mmHg; P less than 0.001), mean arterial blood pressure (from 94.5, s.e.m. = 6.0 to 85.4, s.e.m. = 5.0 mmHg; P less than 0.01), and systemic vascular resistance (from 1690, s.e.m. = 360 to 1420, s.e.m. = 200 dyn. s/cm5; P less than 0.05) and a rise in cardiac index from 1.98 (s.e.m. = 0.07) to 2.28 (s.e.m. = 0.16) litres/min per m2 (P less than 0.05).",Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713738/),[dyn·s] / [cm5],360,236122,DB00457,Prazosin
,6713738,systemic vascular resistance,"Administration of prazosin induced significant decreases in mean pulmonary capillary wedge pressure (from 27.5, s.e.m. = 4.5 to 19.4, s.e.m. = 5.1 mmHg; P less than 0.001), mean arterial blood pressure (from 94.5, s.e.m. = 6.0 to 85.4, s.e.m. = 5.0 mmHg; P less than 0.01), and systemic vascular resistance (from 1690, s.e.m. = 360 to 1420, s.e.m. = 200 dyn. s/cm5; P less than 0.05) and a rise in cardiac index from 1.98 (s.e.m. = 0.07) to 2.28 (s.e.m. = 0.16) litres/min per m2 (P less than 0.05).",Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713738/),[dyn·s] / [cm5],1420,236123,DB00457,Prazosin
,6713738,cardiac index,"Administration of prazosin induced significant decreases in mean pulmonary capillary wedge pressure (from 27.5, s.e.m. = 4.5 to 19.4, s.e.m. = 5.1 mmHg; P less than 0.001), mean arterial blood pressure (from 94.5, s.e.m. = 6.0 to 85.4, s.e.m. = 5.0 mmHg; P less than 0.01), and systemic vascular resistance (from 1690, s.e.m. = 360 to 1420, s.e.m. = 200 dyn. s/cm5; P less than 0.05) and a rise in cardiac index from 1.98 (s.e.m. = 0.07) to 2.28 (s.e.m. = 0.16) litres/min per m2 (P less than 0.05).",Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713738/),[l] / [m2·min],1.98,236124,DB00457,Prazosin
,6713738,cardiac index,"Administration of prazosin induced significant decreases in mean pulmonary capillary wedge pressure (from 27.5, s.e.m. = 4.5 to 19.4, s.e.m. = 5.1 mmHg; P less than 0.001), mean arterial blood pressure (from 94.5, s.e.m. = 6.0 to 85.4, s.e.m. = 5.0 mmHg; P less than 0.01), and systemic vascular resistance (from 1690, s.e.m. = 360 to 1420, s.e.m. = 200 dyn. s/cm5; P less than 0.05) and a rise in cardiac index from 1.98 (s.e.m. = 0.07) to 2.28 (s.e.m. = 0.16) litres/min per m2 (P less than 0.05).",Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713738/),[l] / [m2·min],2.28,236125,DB00457,Prazosin
,6713738,maximum plasma prazosin concentrations,"Pharmacokinetic analysis revealed maximum plasma prazosin concentrations of 4.1 (s.e.m. = 1.4) ng/ml, occurring 2.1 (s.e.m. = 0.4) h after drug ingestion.",Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713738/),[ng] / [ml],4.1,236126,DB00457,Prazosin
,6713738,elimination half-life,"The mean elimination half-life was 5.1 (s.e.m. = 0.8) h, which is longer than that found in our previous studies in normal subjects.",Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713738/),h,5.1,236127,DB00457,Prazosin
,499317,terminal (beta) half-life,The mean terminal (beta) half-life was 2.9 h after intravenous and oral routes.,"Prazosin, pharmacokinetics and concentration effect. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/499317/),h,2.9,238495,DB00457,Prazosin
,499317,Oral bioavailability,Oral bioavailability was 56.9%.,"Prazosin, pharmacokinetics and concentration effect. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499317/),%,56.9,238496,DB00457,Prazosin
,6193359,bioavailability,"The mean predicted bioavailability, based on hepatic clearance and an estimate for liver blood flow, was 74%.",Dose-dependent bioavailability of prazosin in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193359/),%,74,239333,DB00457,Prazosin
,6193359,absolute bioavailabilities,"The mean absolute bioavailabilities, determined for each dose in each animal by comparing dose-corrected areas under the plasma concentration-time curve, were 82, 27, and 23%.",Dose-dependent bioavailability of prazosin in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193359/),%,82,239334,DB00457,Prazosin
,6193359,absolute bioavailabilities,"The mean absolute bioavailabilities, determined for each dose in each animal by comparing dose-corrected areas under the plasma concentration-time curve, were 82, 27, and 23%.",Dose-dependent bioavailability of prazosin in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193359/),%,27,239335,DB00457,Prazosin
,6193359,absolute bioavailabilities,"The mean absolute bioavailabilities, determined for each dose in each animal by comparing dose-corrected areas under the plasma concentration-time curve, were 82, 27, and 23%.",Dose-dependent bioavailability of prazosin in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193359/),%,23,239336,DB00457,Prazosin
,17549677,flow rate,"Levofloxacin and terazosin (internal standard, IS) were chromatographically separated on a C(18) column with a mobile phase containing phosphate buffer (pH 3.0, 10 mm), acetonitrile and triethylamine (76:24:0.076, v/v/v) at a flow rate of 1 mL/min.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),[ml] / [min],1,241319,DB00457,Prazosin
,17549677,retention times,"The retention times of levofloxacin and terazosin were 2.5 and 3.1 min, respectively.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),min,2.5,241320,DB00457,Prazosin
,17549677,retention times,"The retention times of levofloxacin and terazosin were 2.5 and 3.1 min, respectively.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),min,3.1,241321,DB00457,Prazosin
,17549677,recovery,"The recovery ranged from 86 to 89% at the concentrations of 0.0521, 0.5213 and 5.213 microg/mL.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),%,86 to 89,241322,DB00457,Prazosin
,12889528,flow rate,"The mobile phase, 0.02 M sodium phosphate buffer:acetonitrile:tetrahydrofuran = 720:220:60 (v/v/v), was run at a flow rate of 0.8 ml/min and the column effluent was monitored using a florescence detector set at 370 and 250 nm for the emission and excitation wave numbers, respectively.",High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12889528/),,0.8,244347,DB00457,Prazosin
,12889528,retention times,"The retention times for terazosin and prazosin were approximately 6.4 and 9.8 min, respectively, and the coefficients of variation of terazosin were generally low, below 6.4%.",High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12889528/),min,6.4,244348,DB00457,Prazosin
,12889528,retention times,"The retention times for terazosin and prazosin were approximately 6.4 and 9.8 min, respectively, and the coefficients of variation of terazosin were generally low, below 6.4%.",High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12889528/),min,9.8,244349,DB00457,Prazosin
,12889528,area under the plasma concentration-time curve from time zero to time infinity,"Following oral administration of terazosin, 2 mg, to 20 healthy male volunteers, the area under the plasma concentration-time curve from time zero to time infinity was 421 +/- 71.8 ng h/ml and terminal half-life was 9.83 +/- 1.29 h.",High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12889528/),[h·ng] / [ml],421,244350,DB00457,Prazosin
,12889528,terminal half-life,"Following oral administration of terazosin, 2 mg, to 20 healthy male volunteers, the area under the plasma concentration-time curve from time zero to time infinity was 421 +/- 71.8 ng h/ml and terminal half-life was 9.83 +/- 1.29 h.",High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12889528/),h,9.83,244351,DB00457,Prazosin
,32357395,IC50,"The transcellular efflux of prazosin, a stereotypical BCRP substrate, was also significantly reduced in the presence of quercetin in a bidirectional transport assay using human BCRP-overexpressing cells; further kinetic analysis revealed IC50 and Ki values of 4.22 and 3.91 μM, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),μM,4.22,244361,DB00457,Prazosin
,32357395,Ki,"The transcellular efflux of prazosin, a stereotypical BCRP substrate, was also significantly reduced in the presence of quercetin in a bidirectional transport assay using human BCRP-overexpressing cells; further kinetic analysis revealed IC50 and Ki values of 4.22 and 3.91 μM, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),μM,3.91,244362,DB00457,Prazosin
,32357395,AUC8h,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[min∙μg] / [ml],44.5,244363,DB00457,Prazosin
,32357395,AUC8h,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[min∙μg] / [ml],25.7,244364,DB00457,Prazosin
,32357395,Cmax,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[ng] / [ml],179,244365,DB00457,Prazosin
,32357395,Cmax,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[ng] / [ml],122,244366,DB00457,Prazosin
,31796268,total run time,The total run time was about 4.5min which make this method suitable for high throughput analyses.,Validated RP-HPLC method for quantification of doxazosin in human plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31796268/),min,4.5,245049,DB00457,Prazosin
,2525447,elimination half-life,The elimination half-life in plasma was 10.7 +/- 1.2 hours.,Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525447/),h,10.7,246052,DB00457,Prazosin
,16823763,flow rate,"Chromatographic separation was obtained within 8.0 min using a reverse-phase Capcell-Pak C(18) column (150 x 4.6 mm i.d., 5 microm) and the mobile phase consisted of methanol-water containing 10 mM perchloric acid and 1.8 mM sodium heptane sulfonic acid (50:50, v/v) and was set at a flow rate of 1.5 mL/min.",High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16823763/),[ml] / [min],1.5,251520,DB00457,Prazosin
,16823763,recoveries,"Average recoveries of doxazosin and the internal standard from human plasma matrix were 87.0 and 85.9%, respectively.",High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16823763/),%,87.0,251521,DB00457,Prazosin
,16823763,recoveries,"Average recoveries of doxazosin and the internal standard from human plasma matrix were 87.0 and 85.9%, respectively.",High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16823763/),%,85.9,251522,DB00457,Prazosin
,2410686,terminal elimination half-life,"The mean terminal elimination half-life (+/- SD) for prazosin was 2.0 +/- 0.4 h, and that for trimazosin was comparable at 3.1 +/- 0.3 h, whilst the mean terminal elimination half-life for doxazosin was significantly longer at 9.4 +/- 1.5 h.",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),h,2.0,253180,DB00457,Prazosin
,2410686,terminal elimination half-life,"The mean terminal elimination half-life (+/- SD) for prazosin was 2.0 +/- 0.4 h, and that for trimazosin was comparable at 3.1 +/- 0.3 h, whilst the mean terminal elimination half-life for doxazosin was significantly longer at 9.4 +/- 1.5 h.",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),h,3.1,253181,DB00457,Prazosin
,2410686,terminal elimination half-life,"The mean terminal elimination half-life (+/- SD) for prazosin was 2.0 +/- 0.4 h, and that for trimazosin was comparable at 3.1 +/- 0.3 h, whilst the mean terminal elimination half-life for doxazosin was significantly longer at 9.4 +/- 1.5 h.",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),h,9.4,253182,DB00457,Prazosin
,2410686,clearance,"The clearance of prazosin (mean, 327 +/- 78 ml/min) was greater than that of both doxazosin (139 +/- 30 ml/min) and trimazosin (67 +/- 29 ml/min).",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),[ml] / [min],327,253183,DB00457,Prazosin
,2410686,clearance,"The clearance of prazosin (mean, 327 +/- 78 ml/min) was greater than that of both doxazosin (139 +/- 30 ml/min) and trimazosin (67 +/- 29 ml/min).",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),[ml] / [min],139,253184,DB00457,Prazosin
,2410686,clearance,"The clearance of prazosin (mean, 327 +/- 78 ml/min) was greater than that of both doxazosin (139 +/- 30 ml/min) and trimazosin (67 +/- 29 ml/min).",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),[ml] / [min],67,253185,DB00457,Prazosin
,9489594,peak plasma levels,Following ingestion of tamsulosin median peak plasma levels of 16 ng ml(-1) were reached after 5 h and declined to 2 ng ml(-1) at 23.5 h.,Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489594/),[ng] / [ml],16,254848,DB00457,Prazosin
,9489594,peak plasma levels,Following ingestion of tamsulosin median peak plasma levels of 16 ng ml(-1) were reached after 5 h and declined to 2 ng ml(-1) at 23.5 h.,Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489594/),[ng] / [ml],2,254849,DB00457,Prazosin
,9489594,peak plasma levels,Following ingestion of terazosin median peak plasma levels of 91 ng ml(-1) were reached after 1 h and declined to 11 ng ml(-1) at 23.5 h.,Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489594/),[ng] / [ml],91,254850,DB00457,Prazosin
,9489594,peak plasma levels,Following ingestion of terazosin median peak plasma levels of 91 ng ml(-1) were reached after 1 h and declined to 11 ng ml(-1) at 23.5 h.,Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489594/),[ng] / [ml],11,254851,DB00457,Prazosin
,2872815,plasma half-life,"The plasma half-life of terazosin in patients with normal renal function was 10.0 hours, compared with 8.4 hours in patients with moderate renal insufficiency and 9.8 hours in the group with severe renal insufficiency.",Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872815/),h,10.0,254924,DB00457,Prazosin
,2872815,plasma half-life,"The plasma half-life of terazosin in patients with normal renal function was 10.0 hours, compared with 8.4 hours in patients with moderate renal insufficiency and 9.8 hours in the group with severe renal insufficiency.",Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872815/),h,8.4,254925,DB00457,Prazosin
,2872815,plasma half-life,"The plasma half-life of terazosin in patients with normal renal function was 10.0 hours, compared with 8.4 hours in patients with moderate renal insufficiency and 9.8 hours in the group with severe renal insufficiency.",Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872815/),h,9.8,254926,DB00457,Prazosin
,9262356,IC50,"When IUP and MAP blockade effects were plotted against terazosin plasma concentration, direct relationships were observed that were well described by the sigmoidal maximal effect model and resulted in IUP and MAP IC50 values of 48.6 and 12.2 ng/ml, respectively.",Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262356/),[ng] / [ml],48.6,255263,DB00457,Prazosin
,9262356,IC50,"When IUP and MAP blockade effects were plotted against terazosin plasma concentration, direct relationships were observed that were well described by the sigmoidal maximal effect model and resulted in IUP and MAP IC50 values of 48.6 and 12.2 ng/ml, respectively.",Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262356/),[ng] / [ml],12.2,255264,DB00457,Prazosin
,17055685,retention time,"The retention time of doxazosin and the internal standard was 2.7 and 1.8 min, respectively.",LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17055685/),min,2.7,257856,DB00457,Prazosin
,17055685,retention time,"The retention time of doxazosin and the internal standard was 2.7 and 1.8 min, respectively.",LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17055685/),min,1.8,257857,DB00457,Prazosin
,17055685,area under the plasma concentration versus time curve from time 0 to 72 h (AUC(0-72 h)),The area under the plasma concentration versus time curve from time 0 to 72 h (AUC(0-72 h)) 743.4+/-149.5 ngh/ml; peak plasma concentration (C(max)) 47.66 ng/ml; time to C(max) (T(max)) 3.0+/-1.0 h; and elimination half-life (t(1/2)) 18-20 h.,LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17055685/),[ngh] / [ml],743.4,257858,DB00457,Prazosin
,17055685,peak plasma concentration (C(max)),The area under the plasma concentration versus time curve from time 0 to 72 h (AUC(0-72 h)) 743.4+/-149.5 ngh/ml; peak plasma concentration (C(max)) 47.66 ng/ml; time to C(max) (T(max)) 3.0+/-1.0 h; and elimination half-life (t(1/2)) 18-20 h.,LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17055685/),[ng] / [ml],47.66,257859,DB00457,Prazosin
,17055685,time to C(max) (T(max)),The area under the plasma concentration versus time curve from time 0 to 72 h (AUC(0-72 h)) 743.4+/-149.5 ngh/ml; peak plasma concentration (C(max)) 47.66 ng/ml; time to C(max) (T(max)) 3.0+/-1.0 h; and elimination half-life (t(1/2)) 18-20 h.,LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17055685/),h,3.0,257860,DB00457,Prazosin
,17055685,elimination half-life (t(1/2)),The area under the plasma concentration versus time curve from time 0 to 72 h (AUC(0-72 h)) 743.4+/-149.5 ngh/ml; peak plasma concentration (C(max)) 47.66 ng/ml; time to C(max) (T(max)) 3.0+/-1.0 h; and elimination half-life (t(1/2)) 18-20 h.,LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17055685/),h,18-20,257861,DB00457,Prazosin
,8728346,peak plasma concentrations (C(max)),"Mean peak plasma concentrations (C(max)) were 16.98 and 15.76 ng/mL after morning and evening administration, respectively.",Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728346/),[ng] / [ml],16.98,266305,DB00457,Prazosin
,8728346,peak plasma concentrations (C(max)),"Mean peak plasma concentrations (C(max)) were 16.98 and 15.76 ng/mL after morning and evening administration, respectively.",Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728346/),[ng] / [ml],15.76,266306,DB00457,Prazosin
,8728346,area under the plasma concentration-time curve (AUC0-24),"Corresponding mean values of area under the plasma concentration-time curve (AUC0-24) were 227.90 and 253.66 ng.hr/mL, respectively.",Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728346/),[h·ng] / [ml],227.90,266307,DB00457,Prazosin
,8728346,area under the plasma concentration-time curve (AUC0-24),"Corresponding mean values of area under the plasma concentration-time curve (AUC0-24) were 227.90 and 253.66 ng.hr/mL, respectively.",Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728346/),[h·ng] / [ml],253.66,266308,DB00457,Prazosin
greater,15826362,absolute recovery,"Over the concentration range 0.5-20 ng/mL, the absolute recovery values are all greater than 98%.",Improvement of doxazosin determination in human plasma using high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15826362/),%,98,270533,DB00457,Prazosin
